IL-17A (human) LANCE Ultra TR-FRET Detection Kit, 500 Assay Points

The LANCE® Ultra Human IL-17A Detection Kit is designed for detection and quantitation of human IL-17A in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay..The LANCE® Ultra Human IL-17A Detection Kit is designed for detection and quantitation of human IL-17A in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay. No-wash steps, no separation steps TR-FRET technology Sensitive detection High reproducibility Faster time-to-results Easy automation 96-well, 384-well, and 1536-well formats LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. Human Interleukin 17 (IL17 or IL17A) is a homodimer formed of two ~15 kDa subunits produced by a subset of T helper cells named Th17. It is a proinflammatory cytokine that enhances T cell priming and stimulates macrophages, fibroblasts, endothelial and epithelial cells to produce multiple mediators of inflammation like IL1, IL6, TNF-a, NOS-2, metalloproteases, and chemokines. IL17 has been implicated in the proinflammatory patterns associated with joint inflammation and rheumatoid arthritis (RA) in mouse and human models. It is also critical for neutrophil activation and migration, and induces IL8, a key chemokine for neutrophils. IL17 signals through IL-17R, which in mice has at least two members, IL-17RA, and IL-17RC. Recent studies suggest that the IL17 pathway may be a novel therapeutic target for the treatment of chronic inflammatory diseases like asthma and RA.